The rise of Sildenafil initially fueled a boom for the drug industry, but recent shifts present a complicated picture for shareholders. Lower-cost alternatives are reducing earnings, and persistent legal battles add https://marleypfaz048310.blogolenta.com/38223455/the-blue-pill-and-big-pharma-a-volatile-investment